Cyfuse Biomedical K.K. (TYO:4892)

Market Cap	5.41B
Revenue (ttm)	89.00M
Net Income (ttm)	-845.00M
Shares Out	8.30M
EPS (ttm)	-100.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,200
Average Volume	251,795
Open	660.00
Previous Close	676.00
Day's Range	643.00 - 660.00
52-Week Range	446.00 - 1,412.00
Beta	1.52
RSI	58.78
Earnings Date	Feb 13, 2026

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine-related products in Japan and the United States. The company develops cellular products for the regenerative medicine and cellular therapy fields; and undertakes various contracts for research cell products. It also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from ce...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4892

Financial Performance

In 2024, Cyfuse Biomedical K.K.'s revenue was 54.00 million, a decrease of -11.48% compared to the previous year's 61.00 million. Losses were -872.00 million, 48.0% more than in 2023.